These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
395 related items for PubMed ID: 19168351
1. Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings. Chen KX, Vibulbhan B, Yang W, Nair LG, Tong X, Cheng KC, Njoroge FG. Bioorg Med Chem Lett; 2009 Feb 15; 19(4):1105-9. PubMed ID: 19168351 [Abstract] [Full Text] [Related]
5. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. Llinàs-Brunet M, Bailey MD, Bolger G, Brochu C, Faucher AM, Ferland JM, Garneau M, Ghiro E, Gorys V, Grand-Maître C, Halmos T, Lapeyre-Paquette N, Liard F, Poirier M, Rhéaume M, Tsantrizos YS, Lamarre D. J Med Chem; 2004 Mar 25; 47(7):1605-8. PubMed ID: 15027850 [Abstract] [Full Text] [Related]
6. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Njoroge FG, Chen KX, Shih NY, Piwinski JJ. Acc Chem Res; 2008 Jan 25; 41(1):50-9. PubMed ID: 18193821 [Abstract] [Full Text] [Related]
9. Potent and selective small molecule NS3 serine protease inhibitors of Hepatitis C virus with dichlorocyclopropylproline as P2 residue. Chen KX, Vibulbhan B, Yang W, Cheng KC, Liu R, Pichardo J, Butkiewicz N, Njoroge FG. Bioorg Med Chem; 2008 Feb 15; 16(4):1874-83. PubMed ID: 18032054 [Abstract] [Full Text] [Related]
10. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. Raboisson P, Lin TI, Kock Hd, Vendeville S, Vreken WV, McGowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Surleraux D, Wigerinck P, Nilsson M, Rosenquist S, Samuelsson B, Simmen K. Bioorg Med Chem Lett; 2008 Sep 15; 18(18):5095-100. PubMed ID: 18722116 [Abstract] [Full Text] [Related]
13. Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors. Ortqvist P, Peterson SD, Kerblom E, Gossas T, Sabnis YA, Fransson R, Lindeberg G, Helena Danielson U, Karlén A, Sandström A. Bioorg Med Chem; 2007 Feb 01; 15(3):1448-74. PubMed ID: 17113777 [Abstract] [Full Text] [Related]
14. Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile. Arasappan A, Padilla AI, Jao E, Bennett F, Bogen SL, Chen KX, Pike RE, Sannigrahi M, Soares J, Venkatraman S, Vibulbhan B, Saksena AK, Girijavallabhan V, Tong X, Cheng KC, Njoroge FG. J Med Chem; 2009 May 14; 52(9):2806-17. PubMed ID: 19371095 [Abstract] [Full Text] [Related]
19. Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics. Perni RB, Chandorkar G, Cottrell KM, Gates CA, Lin C, Lin K, Luong YP, Maxwell JP, Murcko MA, Pitlik J, Rao G, Schairer WC, Van Drie J, Wei Y. Bioorg Med Chem Lett; 2007 Jun 15; 17(12):3406-11. PubMed ID: 17482818 [Abstract] [Full Text] [Related]